TuHURA Biosciences Enters Material Definitive Agreement
Ticker: HURA · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1498382
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
TuHURA Bio just signed a big deal, filing an 8-K for a Material Definitive Agreement.
AI Summary
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on February 12, 2025, that it entered into a Material Definitive Agreement. The company, incorporated in Nevada with its principal executive offices in Tampa, Florida, is involved in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates a significant new contract or partnership for TuHURA Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities, and their specific nature is not detailed in this initial filing.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- DelMar Pharmaceuticals, Inc. (company) — Former company name
- Berry Only Inc. (company) — Former company name
- February 12, 2025 (date) — Date of earliest event reported
- February 14, 2025 (date) — Filing date
- 10500 University Center Dr., Suite 110 Tampa, Florida 33612 (address) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on February 12, 2025.
When was TuHURA Biosciences, Inc. previously known as Kintara Therapeutics, Inc.?
The date of the name change from Kintara Therapeutics, Inc. to TuHURA Biosciences, Inc. is not explicitly stated in this filing, but the filing is for TuHURA Biosciences, Inc.
What is TuHURA Biosciences, Inc.'s primary industry?
TuHURA Biosciences, Inc. is classified under Pharmaceutical Preparations [2834].
Where are TuHURA Biosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
What is the SEC Act under which this 8-K is filed?
This 8-K is filed pursuant to the Securities Exchange Act of 1934.
Filing Stats: 707 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-14 17:00:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $3,011,372.60 — ") in the aggregate principal amount of $3,011,372.60 as payment of the exercise price of an
Filing Documents
- hura-20250212.htm (8-K) — 51KB
- hura-ex10_1.htm (EX-10.1) — 52KB
- 0000950170-25-021395.txt ( ) — 230KB
- hura-20250212.xsd (EX-101.SCH) — 30KB
- hura-20250212_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 10.1 Form of Warrant Exercise Promissory Note 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: February 14, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer